OneOncology, a partnership of independent oncology practices, has announced the formation of a separate subsidiary, the OneOncology Research Network (OneR). The new platform is a national nonexclusive clinical trial site management organization that will enhance the current research programs underway at participating community oncology practices. OneR provides operational, regulatory, and research support services to more efficiently execute multicenter clinical trials.
Since clinical trials are increasingly integral to the standard of care for precision oncology, the OneR platform will expand the access of community practices to more innovative therapies for their patients. OneR also provides clinical trial sponsors with access to the large and diverse populations of patients with cancer who receive treatment in community centers, rather than the episodic access more common in research-based academic centers. With a majority of cancer care being delivered in community-based centers, OneR ensures diversity in clinical trial participation.
“OneR is a community oncology network designed for and built by community oncology practices,” said Lee Schwartzberg, MD, Chief Medical Officer, OneOncology and Medical Director, West Cancer Center, Memphis. “Our north star is improving the lives of everyone with cancer, which is fundamentally dependent on advancing the science of oncology treatments. We look forward to working with practices and sponsors who want to expand diverse patient access to precision oncology and other high-quality cancer clinical trials through our portfolio of therapeutic and observational studies.”
Lee Schwartzberg, MD
Axel Grothey, MD
Patient Care Plus Progressive Research
OneR’s focus on precision oncology will feature clinical trials across tumor types, offering innovative trial designs based on precision oncology to oncology practices within the network-like basket and umbrella trials. In basket trials, investigators study how well a new drug works in patients who have different types of cancer with the same mutation or biomarker. In umbrella trials, patients with one specific type of cancer receive treatment based on the molecular profile of their individual cancer.
“With too many of our patients disproportionately impacted by health disparities, we believe that by providing community oncology practices with enhanced operational efficiencies we can ensure that more patients will benefit from the groundbreaking clinical trials,” said Axel Grothey, MD, Medical Director, OneR and Director, GI Cancer Research, West Cancer Center. “OneR will not only improve patient access to cutting-edge care, it will also help to advance scientific discovery.”
